Eckert & Ziegler Logo
DE0005659700
565970
EUZ.DE

Eckert & Ziegler

Caricamento quotazioni...

Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Discussioni nella community

  • Aktiensplit: Eckert & Ziegler Strahlen (DE0005659700)

    Sumit Sumit IV in Schnack

    2 11

  • Eckert und Ziegler needs positive Q3 impulses to break downtrend

    The stock of Eckert und Ziegler has moved up from its yearly low but remains in a medium- to long-term downtrend. Analysts at NuWays expect an acceleration of earnings growth ahead of the Q3 results on November 12, driven by higher profitability in the Isotope Products division as well as rising sales of lutetium‑177 and licence income. Technically, the stock must overcome short-term hurdles around €13, just under €14 and the 200-day line at roughly €14.40; on the downside it needs to hold €12.50/€12.60, otherwise a retest of the yearly low at €12 looms. » Altro su finanzen.net


  • Eckert & Ziegler signs supply agreement for terbium-161 with TerThera

    Eckert & Ziegler has signed an agreement with Dutch provider TerThera for the supply of the radionuclide terbium-161 for radioligand therapies. Terbium-161 is to be added to Eckert & Ziegler’s portfolio in Brazil to shorten the supply chain and improve regional access to theranostic solutions. The news helped the stock move off its year low, but a sustainable bottoming has not yet been achieved. » Altro su finanzen.net


  • Eckert und Ziegler confirms 2026 targets, stock remains under pressure

    Eckert und Ziegler has once again confirmed its targets for 2026: revenue around €320 million and adjusted EBIT of about €80 million. Investors are responding cautiously, the stock is generally moving downward and the chart technicals signal further pressure. Adjusted for currency effects and the licensing business, reported revenue and earnings show growth, but real growth is significantly more moderate. » Altro su finanzen.net


  • Eckert und Ziegler face further share losses due to geopolitical risks and missed targets

    Geopolitical tensions in the Gulf are raising energy costs and making transport and logistics more expensive for Eckert und Ziegler, which could dampen demand. Adjusted EBIT after H1 was €33.3m, well below the annual target of around €80m, and revenue has reached €149.3m of the roughly planned €320m. Given this development, strong Q3 figures are unlikely; the stock has been in a downtrend since July and could technically fall from support at around €12.20 to just under €11, though single‑digit prices still appear distant. » Altro su finanzen.net


  • Eckert & Ziegler disappoints with half-year figures and breaks chart support

    Eckert & Ziegler reported only modest revenue growth in the first half of 2026 to €149.3m, with adjusted EBIT down 6% to €33.3m. Targets for 2026 were confirmed, but reaching an adjusted EBIT of around €80m could become riskier after delays in gallium-generator deliveries caused by a cyber attack and a weak Isotope Products segment. The share fell through repeatedly tested levels and broke support at €13.30, putting a further decline toward about €12.40 at risk. Long term, the potential remains intact thanks to large actinium-225 capacities and expansion opportunities in China. » Altro su finanzen.net

Nel 2026, Eckert & Ziegler ha già distribuito 0,22 € di dividendi. L'ultimo pagamento è avvenuto a giugno.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Eckert & Ziegler ha registrato ricavi pari a 79,6 Mln € e un utile netto di 13,1 Mln €
(EUR) settembre 2026
YoY
Ricavi 79,6 Mln 5,69%
Utile lordo 0 100,00%
Utile netto 13,1 Mln 54,90%
EBITDA 19,3 Mln 0,47%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
959,92 Mln €
Numero di azioni
62,58 Mln
Massimo/minimo a 52 settimane
16,84 € - 11,91 €
Rendimento da dividendo
1,43%
Dividendi TTM
0,22 €
Beta
1,47
Rapporto P/E
17,63
Rapporto PEG
0,49
Rapporto P/B
3,58
Rapporto P/S
3,03

Profilo aziendale

Eckert & Ziegler Strahlen- und Medizintechnik AG, tramite le sue controllate, produce e vende componenti per la tecnologia isotopica destinati ad applicazioni mediche, scientifiche e industriali in tutto il mondo. L'azienda opera in due segmenti, Medical e Isotope Products. Il segmento Medical offre piccoli impianti radioattivi per il trattamento del cancro alla prostata, sotto forma di semi, e applicazioni oculari basate su rutenio-106 o iodio-125 per il trattamento del melanoma uveale. Questo segmento fornisce inoltre radiofarmaci, apparecchiature di laboratorio, celle calde e servizi per i radiofarmaci, nonché applicatori oculari e impianti per la prostata. Il segmento Isotope Products produce e vende sorgenti di radiazioni per l'imaging, la tecnologia di misura, l'analisi dei materiali, il controllo di qualità e il monitoraggio ambientale. Questo segmento offre anche sorgenti di calibrazione per i sistemi di imaging medicale, nonché prodotti per la sicurezza nazionale e per la misurazione radiometrica del livello. La società è stata fondata nel 1992 e ha sede a Berlino, in Germania.

Nome
Eckert & Ziegler
CEO
Harald Hasselmann
Sede centrale Berlin, be
Germania
Sito web
Settore
Sanità
Industria
Tecnologia sanitaria
Quotazione in borsa
26/05/1999
Dipendenti 1116

Simboli di borsa

Borsa Simbolo
XETRA
EUZ.DE
Frankfurt
EUZ.F
Düsseldorf
EUZ.DU
Hamburg
EUZ.HM
Milan
1EUZ.MI
London
0NZY.L
SIX
EUZ.SW
München
EUZ.MU
🍪

Parqet  usa i cookie. Scopri di più